IO Biotech Files 8-K on Financials
Ticker: IOBT · Form: 8-K · Filed: Mar 5, 2024 · CIK: 1865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 8-K |
| Filed Date | Mar 5, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: financial-reporting, 8-k
TL;DR
IO Biotech dropped an 8-K detailing its financials - check it for the latest numbers.
AI Summary
IO Biotech, Inc. filed an 8-K on March 5, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located in Copenhagen, Denmark.
Why It Matters
This filing provides an update on IO Biotech's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.
Risk Assessment
Risk Level: low — This is a routine financial filing and does not appear to contain any immediate material adverse events.
Key Players & Entities
- IO Biotech, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of Report
- Copenhagen, Denmark (location) — Principal Executive Offices
- 001-41008 (other) — Commission File Number
FAQ
What specific financial statements are included in this 8-K filing?
The filing indicates that 'Financial Statements and Exhibits' are included, but the specific details of these statements are not provided in the provided text.
What is the primary purpose of this 8-K filing for IO Biotech?
The primary purpose is to report on the 'Results of Operations and Financial Condition' of IO Biotech, Inc.
Where are IO Biotech's principal executive offices located?
IO Biotech's principal executive offices are located at Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.
What is the Commission File Number for IO Biotech?
The Commission File Number for IO Biotech is 001-41008.
Under which sections of the Securities Exchange Act is this 8-K filed?
This Form 8-K is filed pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.
Filing Stats: 535 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2024-03-05 16:46:56
Key Financial Figures
- $0.001 — ich registered Common Stock, par value $0.001 per share IOBT The Nasdaq Stock Mar
Filing Documents
- d747385d8k.htm (8-K) — 25KB
- d747385dex991.htm (EX-99.1) — 86KB
- g747385g0305222241609.jpg (GRAPHIC) — 3KB
- 0001193125-24-059364.txt ( ) — 245KB
- iobt-20240305.xsd (EX-101.SCH) — 3KB
- iobt-20240305_lab.xml (EX-101.LAB) — 17KB
- iobt-20240305_pre.xml (EX-101.PRE) — 11KB
- d747385d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release of the Company dated March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IO BIOTECH, INC. Date: March 5, 2024 By: /s/ Mai-Britt Zocca Name: Mai-Britt Zocca, Ph.D. Title: Chief Executive Officer